User:Mr. Ibrahem/DaxibotulinumtoxinA
| Clinical data | |
|---|---|
| Trade names | Daxxify |
| Other names | Daxi, daxibotulinumtoxinA-lanm |
| License data | |
| Routes of administration | Intramuscular |
| Drug class | Botulinum toxin |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Duration of action | Up to 6 months[2] |
DaxibotulinumtoxinA, sold under the brand name Daxxify, is a medication used to improvement the appearance of wrinkles found between the eyebrows.[1] It may also be given for cervical dystonia.[2] It is given by injection into muscle.[1] Effects may last for up to 6 months.[2]
Common side effects include headache, eyelid dropping, and trouble moving the face.[1] Other side effects may include swallowing or breathing problems.[1] It is a botulinum toxin A which inhibits acetylcholine release and is a neuromuscular blocking agent.[1]
DaxibotulinumtoxinA was approved for medical use in the United States in 2022.[1] It is a commercial competitor to Botox.[3]
References
- ^ a b c d e f g h i "Daxxify- botulinum toxin type a injection, powder, lyophilized, for solution". DailyMed. 19 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
- ^ a b c Solish, N; Carruthers, J; Kaufman, J; Rubio, RG; Gross, TM; Gallagher, CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMID 34787840.
- ^ "U.S. FDA declines to approve Revance's frown-line treatment". Reuters. 15 October 2021. Archived from the original on 17 January 2022. Retrieved 13 December 2022.